Photocure ASA

Jeremy Bahr appointed Chief Business Officer

Oslo, Norway, May 5 2017: Photocure ASA (OSE:PHO), today

announced the appointment of Jeremy Bahr as Chief Business

Officer.

"I am pleased to welcome Jeremy to the Photocure team,

strengthening our strategic, commercial and transactional

capabilities, where he will lead our business development

activities and strategic initiatives within marketing and

market access. Jeremy joins Photocure as Chief Business

Officer with over 20 years of professional experience and I

look forward to working with him as a member of the Photocure

management team," says Kjetil Hestdal, President and Chief

Executive Officer of Photocure.

Bahr comes from UCB, where his most recent role was Global

Head of Market Analytics at UCB, and where he also previously

served as Head of Commercial Operations in North America.

Prior to UCB, he spent 7 years at Pfizer where he held senior

roles within strategy, sales and marketing. Earlier in his

career he worked in private equity, as an entrepreneur and

spent several years as a consultant at McKinsey & Company.

Jeremy Bahr holds an MBA from Harvard Business School, and

bachelor's degrees in Molecular Biology and Political Science

from Brigham Young University.

For further information, please contact:

Photocure

Kjetil Hestdal

President & CEO

Tel: + 47 913 19 535

Erik Dahl

Chief Financial Officer

Tel: +47 450 55 000

Notes to editors

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty

pharmaceutical company focusing on urology. Based on its

unique proprietary Photocure Technology® platform, Photocure

is committed to developing and commercializing highly

selective and minimally invasive solutions to improve health

outcomes for patients worldwide. The company is listed on the

Oslo Stock Exchange (OSE: PHO). Information about Photocure is

available at www.photocure.com.

AI Terminal